Vulvovaginal Candidiasis (VVC)NCT07405853
An Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Vulvovaginal Candidiasis Compared With an Untreated Control Group
A study testing pHyph in people with Vulvovaginal Candidiasis (VVC), run by Gedea Biotech AB at 3 sites in Sweden.
Trial summary
The goal of this clinical trial is to learn if pHyph works to reduce signs and symptoms of vulvovaginal candidiasis (thrush). It will also learn about the safety of pHyph. The main questions it aims to answer are: Does pHyph reduce the signs and symptoms of vulvovaginal candidiasis after an initial 6 day daily… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Vulvovaginal Candidiasis (VVC)
- What is being tested?
- pHyph
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 3 sitesSweden
- Study dates
- 3 Mar 2026to Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing and able to give written informed consent for participation in the clinical investigation, and to comply with all clinical investigation requirements.
- Adult, post-menarchal, pre-menopausal women aged 18 years or older.
- Diagnosis of VVC, defined as:
- Having a white or creamy vaginal discharge, and
- at least two signs (erythema, oedema and excoriation) and/or symptoms (itching, burning irritation) of VVC scored as at least 2 = moderate on a scale of 0-3, and
- potassium hydroxide (KOH) or saline preparation from the inflamed vaginal mucosa or secretions revealing yeast forms (hyphae or pseudohyphae) or budding yeasts upon microscopic analysis.
Show all 10Show fewer
- Negative urine pregnancy test at screening.
- Willing to refrain from using any intravaginal products (e.g., contraceptive creams, gels, foams, sponges, sex toys, lubricants or tampons, etc.) until EOT for the active treatment group (Day 14) or EOI for the no treatment group (Day 7).
- Willing to use condoms during any sexual intercourse with a male sexual partner until EOT for the active treatment group (Day 14) or EOI for the no treatment group (Day 7).
- Willing to use a method of contraception, e.g., condoms, hormonal contraception (oral, injectable, implantable, intravaginal, or transdermal), IUD (if a copper IUD is used, it must be combined with a condom) or intrauterine hormone-releasing system (IUS), during any sexual intercourse that might result in pregnancy from Visit 1 (Day 0) until EOI (Day 25 for the active treatment group or Day 7 for the no treatment group) to prevent pregnancy.
Who cannot join
- Patients with known or apparent signs of other infectious causes of vaginal infection and/or vaginitis (e.g., BV, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, herpes simplex virus or human papillomavirus) at screening.
- History of or presence at screening (Day 0) of any other clinically significant disease or disorder, medical/surgical procedure, or trauma, which, in the opinion of the Investigator, may either put the patient at risk because of participation in the clinical investigation, or influence the results or the patient's ability to participate in the clinical investigation.
- Anticipated menstruation during the first treatment period (Day 0 until Day 7). If a patient is menstruating on Day 0, or if menstruation is anticipated during Days 0 to 7, inclusion can be postponed to an additional visit at a later date when the menstrual bleeding is no longer heavy (light bleeding or brown discharge is acceptable).
- Patients who are pregnant or breastfeeding.
- Patients who are planning to conceive within the 25 days of the investigation.
- Patients who were treated for VVC (both OTC and prescription therapies) within the 14 days preceding screening.
Show all 11Show fewer
- Patients who are currently receiving antifungal therapy unrelated to VVC or have received antifungal therapy within the 14 days preceding screening.
- Patients who have used any pH-modifying vaginal products within the 14 days preceding screening.
- Patients who have received an investigational drug in a clinical trial within 30 days prior to screening.
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, to any of the product components.
- The Investigator considers the patient unlikely to comply with clinical investigation procedures, restrictions and requirements.
Trial locations and contacts
3 sites in 1 country.
About this study
Official title: A Randomised, Partly Blinded Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Vulvovaginal Candidiasis Compared With an Untreated Control Group
The goal of this clinical trial is to learn if pHyph works to reduce signs and symptoms of vulvovaginal candidiasis (thrush). It will also learn about the safety of pHyph. The main questions it aims to answer are:
- Does pHyph reduce the signs and symptoms of vulvovaginal candidiasis after an initial 6 day daily treatment?
- Does an additional 6 day treatment course after the initial one further reduce signs and symptoms of vulvovaginal candidiasis?
- What medical problems do participants have when applying pHyph? Researchers will compare pHyph to no treatment Day 0 to Day 7 to see if pHyph reduces signs and symptoms of vulvovaginal candidiasis. For patients that received initial treatment, researchers will also compare the treatment outcome Day 7 to the treatment outcome after an additional treatment course of pHyph, Day 14.
Read more
Participants will:
- Apply pHyph every day for 6 days or receive no treatment and visit the clinic 7 days after the initial screening visit. Patients that received treatment will continue with pHyph every day for 6 days and patients that did not receive any treatment will receive standard of care for vulvovaginal candidiasis and leave the study.
- Patients that receive pHyph will visit the clinic Day 0 (screening), Day 7, and Day 14, and have a telephone call Day 25. Patients that do not receive pHyph will visit the clinic Day 0 (screening) and Day 7.
- Keep a diary of their symptoms and confirm that they have applied pHyph.
Read the detailed description
- Full title A randomized, partly blinded investigation to evaluate the clinical performance and safety of pHyph in adult women with vulvovaginal candidiasis compared with an untreated control group
- Rationale Vulvovaginal candidiasis (VVC) is a vaginal yeast infection that can cause abnormal vaginal discharge and often itching, affecting up to 75% of all women. Several approved drugs are already available for VVC, but they are not always effective, which means that the infection can recur. Given the limitations of current treatment and prevention strategies for vulvovaginal infections, as well as the high frequency of women misdiagnosing themselves, there is a need for new over-the-counter (OTC) treatment options that can treat both VVC and bacterial vaginosis, are safe during pregnancy, and have a low risk of resistance development. The treatment investigated in this research study is a medical device in the form of a vaginal tablet called pHyph. pHyph contains - glucono-delta-lactone, a substance that occurs naturally in the body, as it is a temporary substance in the breakdown of common sugar. It is also an approved food additive. In pHyph, glucono-delta-lactone causes the acidity (pH value) in the vagina to decrease to normal. In a slightly acidic environment, yeast fungi do not cause VVC in the same extent and lactobacilli are also favored, which can also inhibit yeast fungi. The main aim of the study is to investigate the change in signs and symptoms of VVC after 6 days of treatment with pHyph compared to an untreated control group.
- Objectives
Primary objective:
To evaluate the change in signs and symptoms of VVC after 6 days of treatment with pHyph compared to an untreated control group.
Secondary objectives:
- To further investigate the difference in clinical performance after 6 days of daily treatment with pHyph compared to no treatment (untreated control).
- To investigate the difference in the absence of fungus after 6 days of daily treatment with pHyph compared to no treatment (untreated control).
- To investigate the difference in clinical performance and absence of fungus after 6 days of daily treatment with pHyph compared to longer daily treatment.
- To investigate the safety after a total of 12 days of daily treatment with pHyph as assessed by adverse events.
Exploratory objectives:
To evaluate vaginal microbiome data after 6 days of daily treatment with pHyph compared to no treatment (untreated control group).
To evaluate vaginal microbiome data after 6 days of daily treatment with pHyph compared to longer daily treatment.
- Primary outcome measure The change in vulvovaginal signs and symptoms scores on day 7 compared to day 0.
- By examining for signs of oedema, erythema, or excoriation of the vaginal mucosa and asking the patient about symptoms of itching, burning, and irritation. Signs and symptoms are scored using a rating scale from 0 to 3, at days 0 and 7.
- Secondary outcome measure
The study will compare changes during and after treatment at different time points (days 0, 7, 14, and 25). Among other things, the following will be looked at:
- Presence of vaginal yeast infection
- Number of reported side effects
- Proportion of patients who experience reduction in symptoms such as itching, burning and irritation
- Change in vaginal pH
- How easy and user-friendly the treatment is perceived according to patients' responses in an app Exploratory outcome measure To further evaluate vaginal microbiome data for day 0, day 7, day 14 and day 25.
- Study design The study will include 48 research subjects with Vulvovaginal candidiasis. The research subjects will be divided into 2 groups; 32 who will receive treatment with pHyph and 16 who will receive no treatment at all. After 36 research subjects have been to visit 2, an evaluation of the data will be made. Depending on the outcome, the study can either be terminated or continue to include up to a maximum of 96 additional research subjects.
All research subjects will make 2 visits over a period of approximately 7-9 days. Participants receiving pHyph will have an additional clinic visit and a follow-up telephone call over a period of approximately 22-28 days 7. Study population The study will include women who have menstruated but not yet reached menopause, are 18 years of age or older, and have symptoms of VVC, such as itching, burning, and irritation in the genital area. The diagnosis of VVC is defined as having the following criteria: white or creamy discharge, at least 2 of the following signs and/or symptoms: edema, erythema, excoriations, itching, burning, or irritation of the vaginal mucosa scored at least 2 on a 0-3 rating scale, and visible yeast forms under a microscope. Participants may be recruited through advertising campaigns, social media, and mailings, among other methods. Women with signs of other vaginal infections will not be able to participate in the study.
- Interventions The study involves a maximum of 3 clinical visits and a follow-up telephone call over a period of approximately 25 days, for the treatment group. The untreated group will attend 2 clinic visits. Participants receiving active treatment with pHyph will insert the vaginal tablets themselves at home at bedtime using a CE marked applicator. Detailed instructions will be given at the first visit. At the two (non-treatment group) and three (treatment group) clinical visits on days 0, 7, and 14, a gynecological examination and samples will be taken. Between visits, participants will answer questions about VVC symptoms and treatment via a mobile app.
- Visit 1 (Inclusion visit): study information, consent, and pregnancy test. A gynecological examination and sampling for VVC control will be performed. Participants receiving treatment will receive an applicator and tablets for 6 days of treatment to use at home each evening.
- Visit 2 (Day 7): Gynecological examination and sampling to check for VVC. Participants will answer questions about health and menstruation. Participants who receive treatment will receive additional tablets for 6 days and answer questions about the product's ease of use. Participants who do not receive treatment will end the study after this visit.
- Visit 3 (Day 14): Gynecological examination and sampling for VVC control. Participants are asked to answer questions about health and menstruation and questions about the ease of use of the product.
- Visit 4 (Day 25): Follow-up call by telephone. Participants are asked to answer questions about health and menstruation. Sampling for VVC control is performed by the participants themselves at home. The samples are sent in envelopes by post to the laboratory and the clinic according to instructions.
- Conditions
- Vulvovaginal Candidiasis (VVC)
- Being tested
- pHyph
- Medical subject headings
- Candidiasis, Vulvovaginal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
pHyphDevice
pHyph is a vaginal tablet lowering the vaginal pH
| Study group | Role | What they receive |
|---|---|---|
| pHyph treatment | Active comparator | Application of vaginal tablet every day for 6 days Receives: Device: pHyph |
| No treatment | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The change in CVVS score on Day 7 compared to that on Day 0.
The primary endpoint is defined as the numerical change in the CVVS score on Day 7 compared to that on Day 0.
Each of the of the 6 VVC signs (erythema, oedema and excoriation) and symptoms (itching, burning and irritation) will be scored using the scale below:
- 0 = none (absent)
- 1 = mild (slight)
- 2 = moderate (definitely present)
- 3 = severe (marked, intense)
The CVVS score is the sum of the six individual scores for vulvovaginal signs and symptoms.
Measured: From enrollment to Day 7
Secondary outcomes (16)
The proportion of patients having a reduction in CVVS score
Each of the of the 6 VVC signs (erythema, oedema and excoriation) and symptoms (itching, burning and irritation) will be scored using the scale below: • 0 = none (absent) • 1 = mild (slight) • 2 = moderate (definitely present) • 3 = severe (marked, intense) The CVVS score is the sum of the six individual scores for vulvovaginal signs and symptoms.
Measured: As applicable from enrollment to Day 14
The proportion of patients having a reduction in the sum of the three vulvovaginal symptom scores (itching, burning and irritation).
The score is from 0-3 where 0 = no symptoms and 3 = Severe symptoms
Measured: As applicable from enrollment to Day 25
The sum of the three vulvovaginal symptom scores (itching, burning and irritation).
The score is from 0-3 where 0 = no symptoms and 3 = Severe symptoms
Measured: As applicable from enrollment until Day 25
Individual vulvovaginal symptom scores (itching, burning and irritation).
The score is from 0-3 where 0 = no symptoms and 3 = Severe symptoms
Measured: As applicable from enrollment to Day 25
Other vulvovaginal symptom scores, as self-reported by patients.
Other vulvovaginal symptoms are scored from 0-3 where 0 is no symptoms and 3 is severe symptoms
Measured: As applicable from enrollment to Day 25
The proportion of clinically cured patients, defined as having a CVVS score ≤3.
Each of the of the 6 VVC signs (erythema, oedema and excoriation) and symptoms (itching, burning and irritation) will be scored using the scale below: • 0 = none (absent) • 1 = mild (slight) • 2 = moderate (definitely present) • 3 = severe (marked, intense) The CVVS score is the sum of the six individual scores for vulvovaginal signs and symptoms.
Measured: As applicable from enrollment to Day 14
The proportion of patients showing an absence of fungal hyphae in the wet smear.
Measured: As applicable from enrollment to Day 14
The proportion of mycologically cured patients, defined as vaginal cultures negative for growth of fungal species.
Measured: As applicable from enrollment to Day 25
The proportion of patients having both clinical cure according to secondary endpoint no. 7 as well as mycological cure according to secondary endpoint no. 9.
Measured: As applicable from enrollment to Day 14
The proportion of patients having both clinical cure according to secondary endpoint no. 7 as well as mycologically confirmed fungus at screening.
Measured: As applicable from enrollment to Day 14
The proportion of patients having a CVVS score = 0, i.e., the absence of all signs and symptoms.
Each of the of the 6 VVC signs (erythema, oedema and excoriation) and symptoms (itching, burning and irritation) will be scored using the scale below: • 0 = none (absent) • 1 = mild (slight) • 2 = moderate (definitely present) • 3 = severe (marked, intense) The CVVS score is the sum of the six individual scores for vulvovaginal signs and symptoms.
Measured: As applicable from enrollment to Day 14
The change in CVVS score, i.e., the primary endpoint parameter, for patients that received treatment on Day 7-12.
Each of the of the 6 VVC signs (erythema, oedema and excoriation) and symptoms (itching, burning and irritation) will be scored using the scale below: • 0 = none (absent) • 1 = mild (slight) • 2 = moderate (definitely present) • 3 = severe (marked, intense) The CVVS score is the sum of the six individual scores for vulvovaginal signs and symptoms.
Measured: From enrollment to Day 14
Change in vaginal pH
Measured: As applicable from enrollment to Day 14
The occurrence of vaginal yeasts, assessed by analysis (qPCR) of the vaginal microbiome, i.e., qPCR count of fungal species.
Measured: As applicable from enrollment to Day 25
Reported treatment-emergent adverse events (TEAEs) and device deficiencies in the active treatment group.
Measured: From enrollment to Day 25
Usability, measured by patient questionnaire administered via mobile application on Day 14.
Dichotomous questions and a question regarding general regard of the product using a 10 point scale where 1 is Not satisfied and 10 is Very satisfied
Measured: From enrollment to Day 14
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2026
- Study start3 Mar 2026
- Primary completionOct 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vulvovaginal Candidiasis (VVC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gedea Biotech AB
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- CTC Clinical Trial Consultants AB
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07405853
- Sponsor's protocol ID
- VVC-2025
- Status last verified
- May 2026
- First submitted
- 5 Feb 2026
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Partly Blinded Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Vulvovaginal Candidiasis Compared With an Untreated Control Group
- ClinicalTrials.gov ID
- NCT07405853
- Acronym / sponsor ID
- VVC-2025
- Conditions
- Vulvovaginal Candidiasis (VVC)
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- Gedea Biotech ABIndustry (pharma, biotech, devices)
- Collaborators
- CTC Clinical Trial Consultants AB
- Study start
- 3 Mar 2026 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 12 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if pHyph works to reduce signs and symptoms of vulvovaginal candidiasis (thrush). It will also learn about the safety of pHyph. The main questions it aims to answer are:
- Does pHyph reduce the signs and symptoms of vulvovaginal candidiasis after an initial 6 day daily treatment?
- Does an additional 6 day treatment course after the initial one further reduce signs and symptoms of vulvovaginal candidiasis?
- What medical problems do participants have when applying pHyph? Researchers will compare pHyph to no treatment Day 0 to Day 7 to see if pHyph reduces signs and symptoms of vulvovaginal candidiasis. For patients that received initial treatment, researchers will also compare the treatment outcome Day 7 to the treatment outcome after an additional treatment course of pHyph, Day 14.
Participants will:
- Apply pHyph every day for 6 days or receive no treatment and visit the clinic 7 days after the initial screening visit. Patients that received treatment will continue with pHyph every day for 6 days and patients that did not receive any treatment will receive standard of care for vulvovaginal candidiasis and leave the study.
- Patients that receive pHyph will visit the clinic Day 0 (screening), Day 7, and Day 14, and have a telephone call Day 25. Patients that do not receive pHyph will visit the clinic Day 0 (screening) and Day 7.
- Keep a diary of their symptoms and confirm that they have applied pHyph.
Detailed description
- Full title A randomized, partly blinded investigation to evaluate the clinical performance and safety of pHyph in adult women with vulvovaginal candidiasis compared with an untreated control group
- Rationale Vulvovaginal candidiasis (VVC) is a vaginal yeast infection that can cause abnormal vaginal discharge and often itching, affecting up to 75% of all women. Several approved drugs are already available for VVC, but they are not always effective, which means that the infection can recur. Given the limitations of current treatment and prevention strategies for vulvovaginal infections, as well as the high frequency of women misdiagnosing themselves, there is a need for new over-the-counter (OTC) treatment options that can treat both VVC and bacterial vaginosis, are safe during pregnancy, and have a low risk of resistance development. The treatment investigated in this research study is a medical device in the form of a vaginal tablet called pHyph. pHyph contains - glucono-delta-lactone, a substance that occurs naturally in the body, as it is a temporary substance in the breakdown of common sugar. It is also an approved food additive. In pHyph, glucono-delta-lactone causes the acidity (pH value) in the vagina to decrease to normal. In a slightly acidic environment, yeast fungi do not cause VVC in the same extent and lactobacilli are also favored, which can also inhibit yeast fungi. The main aim of the study is to investigate the change in signs and symptoms of VVC after 6 days of treatment with pHyph compared to an untreated control group.
- Objectives
Primary objective:
To evaluate the change in signs and symptoms of VVC after 6 days of treatment with pHyph compared to an untreated control group.
Secondary objectives:
- To further investigate the difference in clinical performance after 6 days of daily treatment with pHyph compared to no treatment (untreated control).
- To investigate the difference in the absence of fungus after 6 days of daily treatment with pHyph compared to no treatment (untreated control).
- To investigate the difference in clinical performance and absence of fungus after 6 days of daily treatment with pHyph compared to longer daily treatment.
- To investigate the safety after a total of 12 days of daily treatment with pHyph as assessed by adverse events.
Exploratory objectives:
To evaluate vaginal microbiome data after 6 days of daily treatment with pHyph compared to no treatment (untreated control group).
To evaluate vaginal microbiome data after 6 days of daily treatment with pHyph compared to longer daily treatment.
- Primary outcome measure The change in vulvovaginal signs and symptoms scores on day 7 compared to day 0.
- By examining for signs of oedema, erythema, or excoriation of the vaginal mucosa and asking the patient about symptoms of itching, burning, and irritation. Signs and symptoms are scored using a rating scale from 0 to 3, at days 0 and 7.
- Secondary outcome measure
The study will compare changes during and after treatment at different time points (days 0, 7, 14, and 25). Among other things, the following will be looked at:
- Presence of vaginal yeast infection
- Number of reported side effects
- Proportion of patients who experience reduction in symptoms such as itching, burning and irritation
- Change in vaginal pH
- How easy and user-friendly the treatment is perceived according to patients' responses in an app Exploratory outcome measure To further evaluate vaginal microbiome data for day 0, day 7, day 14 and day 25.
- Study design The study will include 48 research subjects with Vulvovaginal candidiasis. The research subjects will be divided into 2 groups; 32 who will receive treatment with pHyph and 16 who will receive no treatment at all. After 36 research subjects have been to visit 2, an evaluation of the data will be made. Depending on the outcome, the study can either be terminated or continue to include up to a maximum of 96 additional research subjects.
All research subjects will make 2 visits over a period of approximately 7-9 days. Participants receiving pHyph will have an additional clinic visit and a follow-up telephone call over a period of approximately 22-28 days 7. Study population The study will include women who have menstruated but not yet reached menopause, are 18 years of age or older, and have symptoms of VVC, such as itching, burning, and irritation in the genital area. The diagnosis of VVC is defined as having the following criteria: white or creamy discharge, at least 2 of the following signs and/or symptoms: edema, erythema, excoriations, itching, burning, or irritation of the vaginal mucosa scored at least 2 on a 0-3 rating scale, and visible yeast forms under a microscope. Participants may be recruited through advertising campaigns, social media, and mailings, among other methods. Women with signs of other vaginal infections will not be able to participate in the study.
- Interventions The study involves a maximum of 3 clinical visits and a follow-up telephone call over a period of approximately 25 days, for the treatment group. The untreated group will attend 2 clinic visits. Participants receiving active treatment with pHyph will insert the vaginal tablets themselves at home at bedtime using a CE marked applicator. Detailed instructions will be given at the first visit. At the two (non-treatment group) and three (treatment group) clinical visits on days 0, 7, and 14, a gynecological examination and samples will be taken. Between visits, participants will answer questions about VVC symptoms and treatment via a mobile app.
- Visit 1 (Inclusion visit): study information, consent, and pregnancy test. A gynecological examination and sampling for VVC control will be performed. Participants receiving treatment will receive an applicator and tablets for 6 days of treatment to use at home each evening.
- Visit 2 (Day 7): Gynecological examination and sampling to check for VVC. Participants will answer questions about health and menstruation. Participants who receive treatment will receive additional tablets for 6 days and answer questions about the product's ease of use. Participants who do not receive treatment will end the study after this visit.
- Visit 3 (Day 14): Gynecological examination and sampling for VVC control. Participants are asked to answer questions about health and menstruation and questions about the ease of use of the product.
- Visit 4 (Day 25): Follow-up call by telephone. Participants are asked to answer questions about health and menstruation. Sampling for VVC control is performed by the participants themselves at home. The samples are sent in envelopes by post to the laboratory and the clinic according to instructions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| pHyph treatment | Active comparator | Device: pHyphApplication of vaginal tablet every day for 6 days |
| No treatment | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Willing and able to give written informed consent for participation in the clinical investigation, and to comply with all clinical investigation requirements.
- Adult, post-menarchal, pre-menopausal women aged 18 years or older.
- Diagnosis of VVC, defined as:
- Negative urine pregnancy test at screening.
- Willing to refrain from using any intravaginal products (e.g., contraceptive creams, gels, foams, sponges, sex toys, lubricants or tampons, etc.) until EOT for the active treatment group (Day 14) or EOI for the no treatment group (Day 7).
Key exclusion criteria (11 listed)
- Patients with known or apparent signs of other infectious causes of vaginal infection and/or vaginitis (e.g., BV, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, herpes simplex virus or human papillomavirus) at screening.
- History of or presence at screening (Day 0) of any other clinically significant disease or disorder, medical/surgical procedure, or trauma, which, in the opinion of the Investigator, may either put the patient at risk because of participation in the clinical investigation, or influence the results or the patient's ability to participate in the clinical investigation.
- Anticipated menstruation during the first treatment period (Day 0 until Day 7). If a patient is menstruating on Day 0, or if menstruation is anticipated during Days 0 to 7, inclusion can be postponed to an additional visit at a later date when the menstrual bleeding is no longer heavy (light bleeding or brown discharge is acceptable).
- Patients who are pregnant or breastfeeding.
- Patients who are planning to conceive within the 25 days of the investigation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| pHyphpHyph is a vaginal tablet lowering the vaginal pH | Device | pHyph treatment |
Primary outcome
The change in CVVS score on Day 7 compared to that on Day 0.
Time frame: From enrollment to Day 7
The primary endpoint is defined as the numerical change in the CVVS score on Day 7 compared to that on Day 0. Each of the of the 6 VVC signs (erythema, oedema and excoriation) and symptoms (itching, burning and irritation) will be scored using the scale below: * 0 = none (absent) * 1 = mild (slight) * 2 = moderate (definitely present) * 3 = severe (marked, intense) The CVVS score is the sum of the six individual scores for vulvovaginal signs and symptoms.
16 secondary outcomes
The proportion of patients having a reduction in CVVS score
Time frame: As applicable from enrollment to Day 14
The proportion of patients having a reduction in the sum of the three vulvovaginal symptom scores (itching, burning and irritation).
Time frame: As applicable from enrollment to Day 25
The sum of the three vulvovaginal symptom scores (itching, burning and irritation).
Time frame: As applicable from enrollment until Day 25
Individual vulvovaginal symptom scores (itching, burning and irritation).
Time frame: As applicable from enrollment to Day 25
Other vulvovaginal symptom scores, as self-reported by patients.
Time frame: As applicable from enrollment to Day 25
The proportion of clinically cured patients, defined as having a CVVS score ≤3.
Time frame: As applicable from enrollment to Day 14
The proportion of patients showing an absence of fungal hyphae in the wet smear.
Time frame: As applicable from enrollment to Day 14
The proportion of mycologically cured patients, defined as vaginal cultures negative for growth of fungal species.
Time frame: As applicable from enrollment to Day 25
The proportion of patients having both clinical cure according to secondary endpoint no. 7 as well as mycological cure according to secondary endpoint no. 9.
Time frame: As applicable from enrollment to Day 14
The proportion of patients having both clinical cure according to secondary endpoint no. 7 as well as mycologically confirmed fungus at screening.
Time frame: As applicable from enrollment to Day 14
The proportion of patients having a CVVS score = 0, i.e., the absence of all signs and symptoms.
Time frame: As applicable from enrollment to Day 14
The change in CVVS score, i.e., the primary endpoint parameter, for patients that received treatment on Day 7-12.
Time frame: From enrollment to Day 14
Change in vaginal pH
Time frame: As applicable from enrollment to Day 14
The occurrence of vaginal yeasts, assessed by analysis (qPCR) of the vaginal microbiome, i.e., qPCR count of fungal species.
Time frame: As applicable from enrollment to Day 25
Reported treatment-emergent adverse events (TEAEs) and device deficiencies in the active treatment group.
Time frame: From enrollment to Day 25
Usability, measured by patient questionnaire administered via mobile application on Day 14.
Time frame: From enrollment to Day 14
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Individual participant dataSharing planned: No
Related trials for Vulvovaginal Candidiasis (VVC)
RecruitingObservational study
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Vulvovaginitis, Candidal, Vulvovaginal Candidiasis
Not yet recruiting
Photobiomodulation for Vaginal Dysfunctions: Home-Based vs Outpatient Treatment
Genitourinary Syndrome of Menopause (GSM), Bacterial Vaginosis
Recruiting
Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis
Vulvovaginal Candidiasis (VVC)
Recruiting
Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)
Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Not yet recruitingObservational study
Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）
Vulvovaginal Candidiasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing pHyph in people with Vulvovaginal Candidiasis (VVC), run by Gedea Biotech AB at 3 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The change in CVVS score on Day 7 compared to that on Day 0. (time frame: From enrollment to Day 7). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.